Fundraising Fox
/Companies
Sign in

Pardes Biosciences

YC S20YC Top Company

San Francisco, US · Founded 2020 · Delaware corporation · 2 employees · Public · 4 known investors

Find your way into Pardes Biosciences

Sign up to see every warm intro you have to Pardes Biosciences

  • Paths you didn't know you had: your email and LinkedIn already hold routes to the Pardes Biosciences team. We find them for you
  • 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
  • Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone

Days of research, done the moment you sign in, with every route ranked by how warm it is.

Sign up with GoogleAlready have an account? Log in

Pardes Biosciences develops oral medications designed to treat and prevent viral infections, including COVID-19.

BiotechHealthtechTherapeuticsUnited States of AmericaAmerica / CanadaFully Remote

Founders & leadership· Y Combinator alumni (S20)

Pardes Biosciences was founded in 2020 by Uri Lopatin and Uri A. Loptain.

ULUri Lopatin
Uri LopatinFounder, Board Member, Strategic and Scientific Advisor2022–2023Uri Lopatin co-founded Assembly Pharma and served as Chief Medical Officer before its merger with Assembly Biosciences in 2014, where he held the role of CMO and VP of R&D and oversaw clinical development of hepatitis B antivirals. He previously worked as a physician-researcher at Schering Plough, Roche, and Gilead Sciences, and completed medical training at UMDNJ, NYU, and the NIH.
UA
Uri A. LoptainCo-founder
HHHeidi Henson
Heidi HensonChief Financial Officer2021–2023Executive Officer at Kura Oncology
EL
Elizabeth LacyExecutive
LA
Lee ArnoldExecutive

Board

JJ
J. Jay LobellBoard director
JB
James B. TananbaumBoard director
MA
Mark AueurbachBoard director
MD
Michael D. VarneyBoard director

Investors · 4

Y Combinatorlisted by Y CombinatorSan Francisco · $500K

How we know: the Y Combinator directory · open dataset · 5k.vc investor directory · Not right? Tell us

Foresite CapitalreportedWest Hollywood

How we know: funding news · Y Combinator's founder network · Not right? Tell us

Khosla VenturesreportedMenlo Park · $100K – $20M

How we know: funding news · Not right? Tell us

Reported raises · per SEC filings

Form D private placements

$51.6M disclosed across 1 round · 2021

▶$51.6MraisedFeb 2021 · 36 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Uri A. LoptainExecutive Officer, Director
  • Mark AueurbachDirector
  • Michael D. VarneyDirector
  • J. Jay LobellDirector
  • Heidi HensonExecutive Officer
  • Elizabeth LacyExecutive Officer
  • Lee ArnoldExecutive Officer
  • James B. TananbaumDirector
Offering amount
$51.6M
Amount sold
$51.6M
First sale
Jan 2021
Incorporated
Corporation, Delaware, 2020
Federal exemptions
06b
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Related companies · 5

Adventris PharmaceuticalsAdventris is a biotechnology company developing cancer immunotherapy treatments.
Kopra BioKopra Bio develops cancer immunotherapy technology that converts cancer cells into biofactories to produce their own destruction. The company operates in the biotech and cancer treatment space.
Felix BiotechnologyFelix Biotechnology develops a digital platform for designing viruses intended to combat antimicrobial resistance.
Valink TherapeuticsValink Therapeutics develops bispecific antibody-drug conjugates (ADCs) for therapeutic applications, combining high-throughput discovery, antibody engineering, and medicinal chemistry capabilities.
Dorian TherapeuticsDorian Therapeutics was a biotechnology startup developing senoblockers, drugs designed to rejuvenate cells and tissues by targeting aging-related mechanisms. Acquired by Altos Labs.

Companies working in the same space as Pardes Biosciences.

Legal entities · 1

corporate structure
Pardes Biosciences, Inc

In the news

Pardes Biosciences Debuts as a Publicly Traded Company Focused on Oral Antiviral Therapies to Potentially Treat and Prevent COVID-19globenewswire.com · Dec 2021

Frequently asked questions

What does Pardes Biosciences do?
Pardes Biosciences develops oral medications designed to treat and prevent viral infections, including COVID-19.
Who founded Pardes Biosciences?
Pardes Biosciences was founded by Uri Lopatin, Uri A. Loptain in 2020.
Who are Pardes Biosciences's investors?
Pardes Biosciences's investors include Frazier Life Sciences, Y Combinator, Foresite Capital, Khosla Ventures.
How much funding has Pardes Biosciences raised?
Pardes Biosciences has disclosed $51.6M raised across 1 round.
Where is Pardes Biosciences headquartered?
Pardes Biosciences is headquartered in San Francisco, US.